Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (mAb) that enhances T cell infiltration and strengthens antitumor immune responses. Cabiralizumab prevents osteoclast activation, thereby inhibiting bone destruction, and is employed in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab has been investigated in combination with Nivolumab in lung cancer studies, highlighting its role in immune-oncology.